Salvage chemotherapy for high-risk gestational trophopblastic tumor

Journal of Reproductive Medicine for the Obstetrician and Gynecologist

Volumn 49, Issue 6, 2004, Pages 438-442

  Matsui, Hideo ^a   Iitsuka, Yoshinori ^a   Suzuka, Kiyomi ^a   Yamazawa, Koji ^a   Mitsuhashi, Akira ^a   Sekiya, Souei ^a  

^a CHIBA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Gestational trophoblastic disease; Gonadotropins, chorionic, human; Pregnancy, molar; Trophoblastic cancer; Trophoblastic neoplasms

Indexed keywords

CHORIONIC GONADOTROPIN; CYCLOPHOSPHAMIDE; DACTINOMYCIN; ETOPOSIDE; FLUOROURACIL; FOLINIC ACID; METHOTREXATE; VINCRISTINE;

ADULT; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; CONFERENCE PAPER; FEMALE; HIGH RISK PATIENT; HUMAN; HYDATIDIFORM MOLE; LEUKOPENIA; LUNG METASTASIS; MORTALITY; PREGNANCY; PRIORITY JOURNAL; REMISSION; THROMBOCYTOPENIA; TREATMENT OUTCOME; TROPHOBLASTIC DISEASE; TROPHOBLASTIC TUMOR;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DACTINOMYCIN; ETOPOSIDE; FEMALE; GESTATIONAL TROPHOBLASTIC NEOPLASMS; HUMANS; LEUCOVORIN; METHOTREXATE; MIDDLE AGED; RISK FACTORS; SALVAGE THERAPY; TREATMENT OUTCOME;

EID: 2942652449     PISSN: 00247758     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (12)

1. Bolis G, Bonazzi C, Landoni F, et al: EMA/CO regimen in high-risk gestational trophoblastic tumor (GTT). Gynecol Oncol 1988;31:439-444
2. Schink JC, Singh DK, Rademaker AW, et al: Etoposide, methotrexate, actinomycin D, cyclophosphamide, and vincristine for the treatment of metastatic, high-risk gestational trophoblastic disease. Obstet Gynecol 1992;80:817-820
3. Soper JT, Evans AC, Clarke-Pearson DL, et al: Alternating weekly chemotherapy with etoposide-methotrexate-dactinomycin-cyclophosphamide- vincristine for high-risk gestational trophoblastic disease. Obstet Gynecol 1994;83:113-117
4. Quinn M, Murray J, Friedlander N, et al: EMACO in high risk gestational trophoblast disease: The Australian experience. Aust N Z J Obstet Gynaecol 1994;34:90-92
5. Bower M, Newlands ES, Holden L, et al: EMA/CO for high-risk gestational trophoblastic tumors: Results from a cohort of 272 patients. J Clin Oncol 1997;15:2636-2643
6. Kim SJ, Bae SN, Kim JH, et al: Effects of multiagent chemotherapy and independent risk factors in the treatment of high-risk GTT: 25 years experiences of KRI-TRD. Int J Gynecol Obstet 1998;60:S85-S96
7. Soto-Wright V, Goldstein DP, Bernstein MR, et al: The management of gestational trophoblastic tumors with etoposide, methotrexate, and actinomycin D. Gynecol Oncol 1997;64:156-159
8. Matsui H, Suzuka K, Iitsuka Y, et al: Combination chemotherapy with methotrexate, etoposide, and actinomycin D for high-risk gestational trophoblastic tumors. Gynecol Oncol 2000;78:28-31
9. Matsui H, Suzuka K, Iitsuka Y, et al: Salvage combination chemotherapy with 5-fluorouracil and actinomycin D for refractory high-risk gestational trophoblastic tumor. Cancer 2002;95:1051-1054
10. Kohorn EI: Negotiating a staging and risk factor scoring system for gestational trophoblastic neoplasia: A progress report. J Reprod Med 2002;47:445-450
11. Sung H, Xia Z, Wu B, et al: 20 years' experience in chemotherapy of choriocarcinoma and malignant mole. Chin Med J 1979;92:677-687
12. Newlands ES, Mulholland PJ, Holden L, et al: Etoposide and cisplatin/etoposide, methotrexate, and actinomycin D (EMA) chemotherapy for patients with high-risk gestational trophoblastic tumors refractory to EMA/cyclophosphamide and vincristine chemotherapy and patients presenting with metastatic placental site trophoblastic tumors. J Clin Oncol 2000;18:854-859